Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx's randomized Phase 2 HexAgon study showed INBRX-106 plus pembrolizumab achieved a 48.3% confirmed objective response rate versus 26.5% for pembrolizumab alone, while six-month progression-free survival was 72.4% versus 42.8%. In HPV-positive patients, the combination produced an 80.0% cORR, 30.0% complete-response rate, and 90.0% six-month PFS, compared with 33.3%, 0%, and 33.0%, respectively, for monotherapy. The company plans to add about 50 HPV-positive OPSCC patients to support a potential accelerated-approval path, followed by FDA alignment and a confirmatory Phase 3 trial.

Analysis

INBX has converted a previously unvalidated immuno-oncology mechanism into a potentially registrational asset, but the valuation debate now shifts from response-rate novelty to reproducibility in a biomarker-defined population. The small HPV-positive subset creates substantial confidence-interval risk; the incremental cohort is therefore the decisive 6-12 month catalyst, not today’s efficacy headline. A durable complete-response signal could support premium strategic value because it offers differentiation from checkpoint-only treatment rather than merely another PD-1 combination.

The near-term share reaction can overshoot because clinical-stage buyers may capitalize the broad solid-tumor and vaccine-combination narrative before there is evidence of transferability. OX40 agonism has a long history of biologic promise with inconsistent clinical translation, and response durability, treatment discontinuations, immune-mediated toxicity, and overall-survival maturity are the key omitted variables. Failure of the expanded cohort to retain a clinically meaningful PFS separation, or an FDA request for a larger randomized dataset before accelerated approval, would sharply lengthen the funding and commercialization timeline.

MRK receives modest strategic optionality if a differentiated add-on expands pembrolizumab-based treatment duration or penetration, but the indication is immaterial to its earnings base; this is not a meaningful MRK trade. BMY and REGN are more exposed competitively only if the program ultimately moves into earlier-stage disease, where a chemotherapy-sparing, biomarker-selected regimen could alter treatment sequencing over a 3-5 year horizon. SNY’s economic exposure appears limited following the prior asset separation, absent a disclosed royalty, equity, or contingent-payment linkage.

Contrarian view: the market may underappreciate the regulatory burden of establishing benefit in a narrow HPV-positive population while overappreciating immediate tumor-agnostic platform value. The cleanest upside case requires the expansion to confirm both efficacy and tolerability across a broader CPS threshold, followed by a credible FDA alignment; neither is de-risked by an interim dataset.

Key Decisions for Investors

• Do not chase INBX in the first-session momentum move. Establish a 3-6 month watch position only after reviewing patient-level durability, discontinuation rates, grade 3+ immune toxicity, and cash runway; size as a binary clinical/regulatory position, with a 50%+ drawdown risk if the expanded HPV-positive cohort regresses toward control-like efficacy.
• For a higher-conviction entry, buy INBX after any post-data consolidation if management provides a funded path through the expanded-cohort readout and the market is valuing INBRX-106 principally as a single-indication asset. Upside is a rerating on FDA meeting clarity; thesis is falsified by a financing requirement before the next material data event or by a materially weaker durability update.
• Avoid using MRK as a direct sympathy long: even successful adoption of INBRX-106 is unlikely to move MRK revenue estimates. Treat any MRK response as sentiment-only unless management identifies a formal development or commercial arrangement.
• Monitor BMY and REGN for longer-dated competitive risk rather than shorting now. Reassess if INBX demonstrates confirmation in earlier-stage HPV-positive disease or announces a registrational design that could displace PD-1 monotherapy; absent that, the addressable population is too narrow for a near-term earnings impact.